MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ASTRAZENECA PHARMA INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
ASTRAZENECA PHARMA Quarterly Results 
(AIDL)
Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ASTRAZENECA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,116 | 1,285 | 1,643 | 1,285 | 1,507 | 1,614 | 1,614 | 2,152 | |
| Other income | Rs m | 64 | 47 | 25 | 27 | 23 | 34 | 34 | 35 | |
| Turnover | Rs m | 1,180 | 1,331 | 1,668 | 1,312 | 1,531 | 1,649 | 1,647 | 2,187 | |
| Expenses | Rs m | 1,163 | 1,222 | 1,286 | 1,394 | 1,355 | 1,522 | 1,466 | 1,743 | |
| Gross profit | Rs m | -47 | 62 | 357 | -108 | 153 | 93 | 148 | 409 | |
| Depreciation | Rs m | 37 | 37 | 37 | 37 | 36 | 36 | 37 | 38 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | -20 | 72 | 344 | -118 | 141 | 92 | 144 | 406 | |
| Tax | Rs m | 9 | 14 | 70 | -15 | 108 | 28 | 53 | 115 | |
| Profit after tax | Rs m | -29 | 58 | 274 | -104 | 32 | 64 | 91 | 291 | |
| Gross profit margin | % | -4.3 | 4.8 | 21.7 | -8.4 | 10.1 | 5.7 | 9.1 | 19.0 | |
| Effective tax rate | % | -44.4 | 19.1 | 20.4 | 12.4 | 77.1 | 30.1 | 36.8 | 28.3 | |
| Net profit margin | % | -2.6 | 4.5 | 16.7 | -8.1 | 2.1 | 4.0 | 5.7 | 13.5 | |
| Diluted EPS | Rs | -1.2 | 2.3 | 11.0 | -4.1 | 1.3 | 2.6 | 3.7 | 11.6 | |
| Diluted EPS (TTM) | Rs | 9.8 | 7.9 | 18.5 | 8.0 | 10.4 | 10.7 | 3.4 | 19.1 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ASTRAZENECA PHARMA 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: PLETHICO PHARMA ORCHID PHARMA LTD GLENMARK PHARMA SUN PHARMA NATCO PHARMA
Compare ASTRAZENECA PHARMA With: PLETHICO PHARMA ORCHID PHARMA LTD GLENMARK PHARMA SUN PHARMA NATCO PHARMA
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens in Green; Tata Steel and Axis Bank Top Gainers(09:30 am)
Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.7% while the Hang Seng is down 0.1%.
Views on news
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My Master Series on How to Trade Election 2019(Profit Hunter)
Apr 16, 2019For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...
Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)
Apr 17, 201920% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.
The Best Trading Strategy in the World(Profit Hunter)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
L&T: Should Corporates have a Conscience?(The Honest Truth)
Apr 22, 2019Ajit Dayal believes L&T is taking a risky path and risking not only the culture established at MindTree but the fragile eco system that could endanger the lives of millions of residents in Mumbai.
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Apr 26, 2019 11:49 AM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - MERCK COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.